

#### Parametric study of the impact of intracellular radionuclide distribution in Targeted Alpha Therapy, with multi-scale modeling

Victor Levrague, Mario Alcocer-Avila, Sarah Otmani, Lydia Maigne, Etienne Testa, Michaël Beuve, Rachel Delorme

#### ► To cite this version:

Victor Levrague, Mario Alcocer-Avila, Sarah Otmani, Lydia Maigne, Etienne Testa, et al.. Parametric study of the impact of intracellular radionuclide distribution in Targeted Alpha Therapy, with multi-scale modeling. 17th International Congress for Radiation Research (ICRR), Aug 2023, Montréal, Canada. . hal-04305468

#### HAL Id: hal-04305468 https://hal.science/hal-04305468v1

Submitted on 24 Nov 2023  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# Parametric modeling study of the impact of intracellular radionuclide distribution in targeted alpha therapy



**GRENOBLE** MODANE

<u>Victor Levraque<sup>1</sup>, Mario Alcocer-Avila<sup>2</sup>, Sarah Otmani<sup>1</sup>, Lydia Maigne<sup>3</sup>, Etienne Testa<sup>2</sup>, Michaël Beuve<sup>2</sup>, Rachel Delorme<sup>1</sup></u>

1: Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France 2: IP2I, Université Claude Bernard Lyon 1, CNRS/IN2P3, 69622 Villeurbanne, France

3: Université Clermont Auvergne, CNRS/IN2P3, LPC, 63000 Clermont-Ferrand, France



## Context

**Targeted Alpha Therapy:** Vectorization of an **α-emitter** radionuclide in **tumors** thanks to **targeting** pharmaceutical **agent** 

Heterogeneous dose deposition at the **micro-metric** scale: Two identical macroscopic doses ≠ two identical biological effects



### **Proposed method to predict biological effects:**

Combination of biophysical modeling and Monte-Carlo simulations at the micrometric scale

## **Objectives**

## **Materials & Methods**

**GEANT** [2] **CPCP**<sup>[1]</sup>



• Generation of high cellular density **3D spheroid**, with **CPOP** 



Spheroid with 75% compaction and 3069 cells

### Cell survival prediction model • Nucleus = sensitive volume

Nanodosimetry		Microdosimetry		
Lethal	local	Subletha	al global	

Study the **impact** of **intracellular radionuclide distribution** on the efficiency of TAT as a function of influence parameters



**Observables:** Physical dose (also called specific energy, at the *microscopic scale*), cell survival, tumor control probability (cell line: Human Salivary Gland)

- Monte-Carlo simulations of alpha particles in cells, with Geant4 - CPOP
- **Output:** physical doses, entrance  $E_i$ and exit  $E_f$  kinetic energies for each nucleus traversal of an alpha particle



Geant4 simulation of an alpha particle crossing a cell nucleus

Januye

- Takes into account **variation** of damage density with the ion's energy
- **Output:**  $(\alpha, \beta)$  radiobiological coefficients

Combined calculations of **cell** survivals S and TCP :

 $S = f((\alpha, \beta), (E_i, E_f))$ 

 $TCP = \prod_{k=1}^{n} S_k$ 

## **Results and Discussion**

A-1: Impact of geometry and irradiation parameters on nucleus physical dose, according to radionuclide internalization



**B-1: Tumor Control Probability as a function of activity per cell** 



- Low impact of cytoplasm only internalization
- Moderate impact of nucleus only internalization
- High impact of small and low compaction spheroid

## A-2: Quantification of cross-fire irradiation

Mean nucleus physical dose increase of cytoplasm and nucleus radionuclide source distribution compared to membrane source distribution only.

<u>Default parameters:</u> 95µm radius spheroid, 75% compaction, irradiated by At-211. In each plot, one parameter was changed at a time.

> Tumor control probability as a function of the activity per cell (mBq). The simulations were performed in a 95µm radius spheroid, with 75% compaction, irradiated by At-211.

- **Threshold effect** around 0.15 mBg per cell
- At 0.15 mBq per cell: ~ **18 fold higher TCP** between **nucleus** and membrane source distribution
- D 2. DDEu of alpha partialas in the condition of an 211At TAT

<ul> <li>Self nucleus dose 35.00%</li> <li>65.00%</li> <li>Cross nucleus dose</li> <li>In this study ≈ 65 to 98% of total irradiation</li> <li>→ Cross-fire effect more important than intracellular distribution due to high range of alpha particles</li> <li>Minimum observed cross-fire nucleus dose %: 30µm radius spheroid</li> </ul>	<b>B-2: RBEµ of alpha particles in the condition of allAt TAT</b> <b>treatment</b> <b>RBEµ = 6.9</b> <i>RBEµ value found at 10% cell</i> <i>survival, for a membrane source</i> <i>distribution</i> <i>RBEµ = <math>\frac{-\alpha_{ref} + \sqrt{\alpha_{ref}^2 + 4 \cdot \beta_{ref} \cdot (\alpha \cdot D + \beta \cdot D^2)}}{2 \cdot \beta_{ref} \cdot D}</math></i> <b>High biological impact</b> of <b>alpha</b> particle, confirmed by literature [4].		
Conclusions	Perspectives		
<ul> <li>Cross-fire effect major in targeted alpha therapy</li> <li>Intracellular radionuclide distribution must be precisely modeled for small tumors (&lt; 50µm radius), especially with low radionuclide concentration</li> <li>Biological quantities mandatory to consider, in addition to physical ones</li> </ul>	<ul> <li>Modeling of intratumoral heterogeneity of radionuclide distribution</li> <li>Validation against experimental data</li> <li>Modeling radionuclide diffusion kinetic</li> </ul>		

### References

[1] Maigne, L., et al. *Physica Medica* 89 (2021): 41-50 [2] Agostinelli, Sea, et al. Nucl. Instrum. Methods. Phys. Res. B NUCL INSTRUM METH A506.3 (2003): 250-303.Z

#### [3] Cunha, Micaela, et al. Physics in Medicine & Biology 62.4 (2017): 1248. [4] Loucas, Bradford D., et al. Radiation research 179.1 (2013): 9-20.

**Contact:** <u>victor.levrague@lpsc.in2p3.fr</u>

**ICRR-17: 27-30 august 2023**